Fox Chase Cancer Center | Strategic Alliance Partners

January 29, 2020

Hossein Borghaei, DO, MS, discusses immunotherapy alone or in combination with chemotherapy in combination with immunotherapy in patients with advanced NSCLC.

January 03, 2020

Hossein Borghaei, DO, MS, discusses immune-related adverse events in patients with lung cancer who received immunotherapy/chemotherapy combinations.

November 16, 2019

Hossein Borghaei, DO, MS, discusses emerging biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

October 17, 2019

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses the clinical utility of PD-L1 in advanced non–small cell lung cancer (NSCLC).

October 05, 2019

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses necessary research and anticipated trials evaluating immunotherapy in advanced non–small cell lung cancer (NSCLC).

October 02, 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving yet relevant role of surgery in renal cell carcinoma.

October 01, 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving role of surgery in metastatic kidney cancer.

September 25, 2019

Hossein Borghaei, DO, discusses pivotal and ongoing trials driven by biomarkers in lung cancer.

August 09, 2019

Michael J. Hall, MD, Fox Chase Cancer Center, discusses the emergence of PARP inhibition in the armamentarium for patients with pancreatic cancer.

July 15, 2019

Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.

June 26, 2019

Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.

March 30, 2019

Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.

March 28, 2019

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.

January 17, 2019

Within 6 months of receiving induction chemotherapy, consolidation treatment with autologous hematopoietic cell transplantation correlated with a significant improvement in progression-free survival in younger, fit patients with mantle cell lymphoma.

October 30, 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the current landscape of immunotherapy in non–small cell lung cancer (NSCLC).

October 12, 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses molecular profiling in lung cancer.

August 17, 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

August 06, 2018

Hossein Borghaei, DO, MS, discusses the results of the subgroup analysis of the ongoing CheckMate-227 trial in metastatic non–small cell lung cancer.

July 25, 2018

Jessica Bauman, MD, addresses current and emerging therapeutic options for patients with BRAF, ROS1, and RET abnormalities in non–small cell lung cancer.

July 04, 2018

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).